STOCKNO.DE
Institutional ownership intelligence
Research
Schedule 13G

SLNOEUR Schedule 13G filing by T. Rowe Price Associates

T. Rowe Price Associates reported beneficial ownership of 2.4M shares, representing 12% of SOLENO THERAPEUTICS INC in this filing.

FiledMay 14, 2025
Ownership dateMar 31, 2025
Reported shares2.4M
Reported ownership12%
Ownership details

Voting and dispositive power reported in the filing

These figures describe the reporting filer’s disclosed voting and investment authority. They should be read together with the reported share count and percentage.

Sole voting power 2.4M
Shared voting power 2.4M
Sole dispositive power 2.4M
Shared dispositive power 2.4M
Source

Original filing and accession

Use the SEC filing as the primary source when you need the complete disclosure, footnotes, exhibits, or reporting-person details.

Reporting filer
T. Rowe Price Associates
CIK
CIK0000080255
Accession
0000080255-25-000364
Form
Schedule 13G
Open SEC filing View SLNOEUR ownership history
Read the filing in context

Understand what a Schedule 13 filing does—and does not—tell you.

How to read a Schedule 13G → Does a 13G mean the shares were just bought? → Filing date vs. ownership date →